| Literature DB >> 24070055 |
Basem Azab1, Masood A Shariff, Rana Bachir, John P Nabagiez, Joseph T McGinn.
Abstract
BACKGROUND: Neutrophil lymphocyte ratio (NLR) is a predictor of major adverse cardiovascular outcomes. Our study explores the value of NLR in predicting long-term mortality after minimally invasive coronary artery bypass surgery (MICS) via lateral left-thoracotomy versus conventional sternotomy coronary artery bypass grafting (CABG) surgery.Entities:
Mesh:
Year: 2013 PMID: 24070055 PMCID: PMC3850883 DOI: 10.1186/1749-8090-8-193
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Baseline characteristics (demographic and presentation) of coronary artery bypass patients according to neutrophil lymphocyte ratios (NLR) and surgical approach (MICS vs. Sternotomy CABG)
| n | 242 | 129 | | 245 | 130 | | 243 | 137 | |
| Age (years) | 62.5 ± 10.2 | 60.7 ± 10.9 | 0.12 | 64.3 ± 11.0 | 62.6 ± 10.7 | 0.14 | 67.5 ± 11.0 | 65.6 ± 10.7 | 0.10 |
| Male | 174 (71.9%) | 90 (69.8%) | 0.67 | 172 (70.5%) | 93 (71.0%) | 0.92 | 178 (73.3%) | 100 (73.0%) | 0.96 |
| Race (Caucasian) | 200 (82.6%) | 106 (82.2%) | 0.09 | 218 (89.3%) | 123 (93.9%) | 0.14 | 227 (93.4%) | 128 (93.4%) | 1.00 |
| Body Mass Index (kg/m2) | 29.1 ± 5.09 | 29.4 ± 5.42 | 0.65 | 30.0 ± 5.70 | 29.9 ± 6.22 | 0.95 | 28.8 ± 5.50 | 28.7 ± 5.71 | 0.81 |
| Death | 21 (8.7%) | 9 (7.0%) | 0.57 | 32 (13.1%) | 17 (13.0%) | 0.97 | 57 (23.5%) | 18 (13.1%) | 0.02 |
| Family history of CAD | 101 (41.7%) | 63 (48.8%) | 0.19 | 79 (32.4%) | 45 (34.4%) | 0.7 | 89 (36.6%) | 41 (29.9%) | 0.19 |
| Smoking | 149 (62.9%) | 65 (50.4%) | 0.02 | 141 (59.7%) | 72 (55.4%) | 0.42 | 134 (55.6%) | 69 (50.4%) | 0.33 |
| Hypertension | 172 (71.1%) | 98 (76.6%) | 0.26 | 180 (74.1%) | 93 (71.0%) | 0.52 | 181 (74.5%) | 113 (83.1%) | 0.05 |
| Diabetes mellitus | 94 (38.8%) | 33 (25.6%) | 0.01 | 73 (29.9%) | 33 (25.2%) | 0.33 | 96 (39.5%) | 47 (34.3%) | 0.32 |
| Peripheral arterial disease | 29 (12.0%) | 13 (10.1%) | 0.58 | 36 (14.8%) | 7 (5.3%) | 0.006 | 39 (16.0%) | 14 (10.2%) | 0.12 |
| Renal failure on dialysis | 3 (1.2%) | 1 (0.8%) | 0.68 | 3 (1.2%) | 5 (3.8%) | 0.1 | 8 (3.3%) | 9 (6.6%) | 0.14 |
| Myocardial infarction | 134 (55.4%) | 51 (39.5%) | 0.004 | 132 (54.1%) | 52 (39.7%) | 0.008 | 130 (53.5%) | 38 (27.7%) | <0.001 |
| History of PCI | 71 (29.3%) | 23 (17.8%) | 0.02 | 66 (27.0%) | 31 (23.7%) | 0.48 | 58 (23.9%) | 23 (16.8%) | 0.11 |
| Prior CABG | 7 (2.9%) | 2 (1.6%) | 0.51 | 7 (2.9%) | 1 (0.8%) | 0.27 | 9 (3.7%) | 2 (1.5%) | 0.34 |
| Prior heart failure | 37 (15.3%) | 7 (5.4%) | 0.005 | 41 (16.8%) | 9 (6.9%) | 0.007 | 45 (18.5%) | 11 (8.0%) | 0.01 |
| Prior cerebrovascular event | 31 (12.8%) | 8 (6.2%) | 0.048 | 39 (16.0%) | 11 (8.4%) | 0.04 | 50 (20.6%) | 12 (8.8%) | 0.003 |
| C0PD | 30 (12.4%) | 10 (7.9%) | 0.18 | 34 (13.9%) | 16 (12.2%) | 0.64 | 34 (14.0%) | 16 (11.7%) | 0.52 |
| Preoperative CCS | | | | | | | | | |
| none | 0 (0%) | 1 (0.8%) | 0.14 | 2 (0.8%) | 0 (0%) | 0.02 | 2 (0.8%) | 0 (0%) | <0.001 |
| Class I | 42 (17.6%) | 24 (18.6%) | | 34 (13.9%) | 32 (24.4%) | | 41 (17.2%) | 28 (20.6%) | |
| Class II | 61 (25.5%) | 45 (34.9%) | | 74 (30.3%) | 47 (35.9%) | | 46 (19.3%) | 49 (36.0%) | |
| Class III | 68 (28.5%) | 33 (25.6%) | | 75 (30.7%) | 29 (22.1%) | | 83 (34.9%) | 45 (33.1%) | |
| Class IV | 68 (28.5%) | 26 (20.2%) | | 59 (24.2%) | 23 (17.6%) | | 66 (27.7%) | 14 (10.3%) | |
| NYHA | | | | | | | | | |
| Class I | 22 (17.9%) | 21 (19.4%) | 0.21 | 25 (29.2%) | 25 (24.0%) | 0.31 | 30 (23.8%) | 22 (21.2%) | 0.03 |
| Class II | 33 (26.8%) | 40 (37.0%) | | 42 (32.3%) | 39 (37.5%) | | 26 (20.6%) | 33 (31.7%) | |
| Class III | 44 (35.8%) | 26 (24.1%) | | 37 (28.5%) | 19 (18.3%) | | 38 (30.2%) | 37 (35.6%) | |
| Class IV | 24 (19.5%) | 21 (19.4%) | | 26 (20.0%) | 21 (20.2%) | | 32 (25.4%) | 12 (11.5%) | |
| Ejection Fraction (%) | 39.8 ± 12.1 | 41.0 ± 10.8 | 0.32 | 39.1 ± 12.1 | 41.6 ± 10.4 | 0.04 | 39.3 ± 12.8 | 41.2 ± 12.4 | 0.17 |
| Preoperative laboratory values | | | | | | | | | |
| Leukocyte (k/cc) | 7.42 ± 2.31 | 7.20 ± 2.03 | 0.37 | 8.09 ± 2.22 | 7.61 ± 2.20 | 0.05 | 9.70 ± 3.13 | 8.87 ± 2.71 | 0.01 |
| Neutrophils (k/cc) | 4.06 ± 1.35 | 3.94 ± 1.29 | 0.40 | 5.28 ± 1.55 | 4.97 ± 1.51 | 0.06 | 7.45 ± 2.82 | 6.76 ± 2.45 | 0.01 |
| Lymphocytes (k/cc) | 2.45 ± 1.10 | 2.40 ± 0.763 | 0.40 | 1.91 ± 0.566 | 1.79 ± 0.533 | 0.06 | 1.35 ± 0.462 | 1.29 ± 0.455 | 0.24 |
| Monocytes (k/cc) | 0.62 ± 0.286 | 0.62 ± 0.241 | 0.80 | 0.65 ± 0.263 | 0.60 ± 0.225 | 0.12 | 0.69 ± 0.299 | 0.62 ± 0.237 | 0.02 |
| Creatinine (mg/dl) | 1.06 ± 0.741 | 1.07 ± 0.983 | 0.99 | 1.14 ± 0.711 | 1.19 ± 1.02 | 0.56 | 1.26 ± 0.61 | 1.18 ± 0.604 | 0.06 |
| Glucose (mg/dl) | 124.0 ± 48.9 | 122.4 ± 52.4 | 0.76 | 126.1 ± 49.3 | 110.8 ± 41.6 | 0.002 | 136.2 ± 58.8 | 121.5 ± 46.3 | 0.01 |
CABG coronary artery bypass grafting, CAD coronary artery disease, CCS Canadian Cardiovascular Society Angina classification system, COPD chronic obstructive pulmonary disease, NYHA New York Heart Association Functional Classification, PCI percutaneous coronary intervention. Categorical variables were presented as frequencies and percentages; continuous variables were presented as means and standard deviations.
Operative and post-operative characteristics (management and laboratory) of coronary artery bypass patients according to neutrophil lymphocyte ratios (NLR) and surgical approach (MICS vs. Sternotomy CABG)
| 242 | 129 | | 245 | 130 | | 243 | 137 | | |
| | | | | | | | | ||
| Aspirin | 238 (98.3%) | 128 (99.2%) | 0.66 | 234 (95.9%) | 130 (100%) | 0.02 | 237 (97.5%) | 137 (100%) | 0.09 |
| Clopidogrel | 110 (45.5%) | 111 (86.0%) | <0.001 | 128 (52.5%) | 115 (88.5%) | <0.001 | 120 (49.4%) | 116 (84.7%) | <0.001 |
| Beta-blockers | 232 (95.9%) | 124 (96.1%) | 0.91 | 230 (94.3%) | 128 (98.5%) | 0.06 | 231 (95.1%) | 135 (98.5%) | 0.08 |
| Angiotensin convertase inhibitor | 84 (34.7%) | 44 (34.1%) | 0.91 | 96 (39.3%) | 31 (23.8%) | 0.00 | 104 (42.8%) | 45 (32.8%) | 0.06 |
| Angiotensin receptor blocker | 29 (12.0%) | 13 (10.1%) | 0.58 | 17 (7.0%) | 13 (10.0%) | 0.30 | 19 (7.8%) | 17 (12.4%) | 0.14 |
| Warfarin | 18 (7.4%) | 7 (5.4%) | 0.46 | 18 (7.4%) | 8 (6.2%) | 0.66 | 26 (10.7%) | 9 (6.6%) | 0.18 |
| Statin | 232 (95.9%) | 127 (98.4%) | 0.23 | 229 (93.9%) | 126 (96.9%) | 0.20 | 228 (93.8%) | 132 (96.4%) | 0.29 |
| | | | | | | | | ||
| Aspirin | 237 (98.3%) | 125 (97.7%) | 0.70 | 234 (95.9%) | 127 (97.7%) | 0.56 | 230 (95.4%) | 131 (97.8%) | 0.26 |
| Clopidogrel | 66 (27.4%) | 101 (78.9%) | <0.001 | 83 (34.0%) | 105 (80.8%) | <0.001 | 64 (26.6%) | 104 (77.6%) | <0.001 |
| Beta-blockers | 212 (88.0%) | 114 (89.1%) | 0.76 | 216 (88.5%) | 117 (90.0%) | 0.66 | 208 (86.3%) | 123 (91.8%) | 0.11 |
| Angiotensin convertase inhibitor | 70 (29.0%) | 32 (25.0%) | 0.41 | 67 (27.5%) | 24 (18.5%) | 0.05 | 75 (31.1%) | 27 (20.1%) | 0.02 |
| Angiotensin receptor blocker | 1 (0.4%) | 4 (3.1%) | 0.05 | 4 (1.7%) | 1 (0.8%) | 0.66 | 2 (0.8%) | 7 (5.2%) | 0.01 |
| Warfarin | 30 (12.4%) | 17 (13.3%) | 0.82 | 27 (11.1%) | 12 (9.2%) | 0.58 | 43 (17.8%) | 11 (8.2%) | 0.01 |
| Statin | 220 (91.3%) | 119 (93.0%) | 0.57 | 222 (91.0%) | 120 (92.3%) | 0.66 | 218 (90.5%) | 123 (91.8%) | 0.67 |
| | | | | | | | | | |
| Internal mammary artery utilized | 231 (95.5%) | 127 (98.4%) | 0.23 | 230 (94.3%) | 128 (97.7%) | 0.13 | 221 (90.9%) | 134 (97.8%) | 0.01 |
| Number of conduits used for bypass | 3.28 ± 0.991 | 2.12 ± 0.673 | <0.001 | 3.26 ± 0.886 | 2.28 ± 0.806 | <0.001 | 3.12 ± 0.910 | 2.17 ± 0.753 | <0.001 |
| Cardiopulmonary bypass | 27 (11.2%) | 6 (4.7%) | 0.04 | 30 (12.3%) | 7 (5.3%) | 0.03 | 18 (7.4%) | 8 (5.8%) | 0.56 |
| | | | | | | | | ||
| Renal Failure on Dialysis | 1 (0.4%) | 2 (1.6%) | 0.28 | 3 (1.2%) | 4 (3.1%) | 0.25 | 12 (4.9%) | 3 (2.2%) | 0.19 |
| New onset atrial fibrillation | 33 (13.6%) | 22 (17.1%) | 0.38 | 40 (16.4%) | 30 (22.9%) | 0.12 | 48 (19.8%) | 43 (31.4%) | 0.01 |
| Septicemia | 0 (0%) | 5 (3.9%) | 0.005 | 0 (0%) | 2 (1.5%) | 0.12 | 6 (2.5%) | 2 (1.5%) | 0.72 |
Categorical variables were presented as frequencies and percentages; continuous variables were presented as means and standard deviations. CABG coronary artery bypass grafting.
Figure 1The 5-year all-cause mortality after coronary bypass surgery according to preoperative neutrophil lymphocyte ratio (NLR) and surgical approach(MICS vs. Sternotomy CABG). According to Fisher’s exact test the 5-year mortality rates were higher in the sternotomy CABG patients with NLR >3.4 compared to MICS with NLR >3.4 (p value <0.0001 ). MICS = minimal invasive cardiac surgery; CABG = coronary artery bypass grafting. The average follow-up was 49 ± 15.2 months (range 21–70 months). Total of 467 patients had 5-year follow up period.
Figure 2Kaplan-Meier Curve of mortality among patients undergoing coronary artery bypass surgery according to their neutrophil lymphocyte ratio (NLR) tertiles. Log rank (Mantel-Cox) p < 0.0001. The average follow-up was 49 ± 15.2 months (range 21–70 months). Total of 467 patients had 5-year follow up period.
Hazard ratios of baseline characteristics for all-cause mortality among coronary artery bypass surgery patients (univariate analysis)
| Male | 0.63 (0.45–0.87) | 0.005 |
| Age (per year) | 1.06 (1.06–1.09) | <0.001 |
| Race (Caucasian) | 1.40 (0.78-2.53) | 0.26 |
| Body Mass Index (kg/m2) (31+) | | |
| 18–25 | 1.35 (0.90–2.03) | 0.14 |
| 26–30 | 1.11 (0.75–1.64) | 0.60 |
| Ejection fraction (%) | 1.01 (0.99–1.02) | 0.46 |
| Hypertension | 1.31 (0.89–1.93) | 0.17 |
| Smoking | 0.89 (0.65–1.23) | 0.48 |
| Chronic pulmonary disease | 2.02 (1.37–2.96) | <0.001 |
| Prior myocardial infarction | 1.00 (0.73–1.37) | 0.99 |
| Prior coronary angioplasty | 1.16 (0.81–1.65) | 0.41 |
| Prior coronary artery bypass graft | 0.67 (0.21–2.09) | 0.48 |
| Congestive heart failure | 1.64 (1.11–2.43) | 0.01 |
| Prior cerebrovascular event | 1.79 (1.22–2.62) | 0.003 |
| Family history of coronary artery disease | 0.56 (0.39–0.80) | 0.001 |
| Renal Failure on Dialysis | 3.95 (2.19–7.12) | <0.001 |
| Diabetes Mellitus | 1.60 (1.17–2.21) | 0.004 |
| Peripheral arterial disease | 1.39 (0.91–2.14) | 0.12 |
| Pre-Operative CCS | 1.01 (0.87–1.18) | 0.85 |
| Pre-Operative NYHA | 0.86 (0.71–1.06) | 0.15 |
| Pre-Operative Leukocyte | 1.05 (0.99–1.11) | 0.11 |
| Pre-Operative Neutrophils | 1.08 (1.02–1.15) | 0.01 |
| Pre-Operative Lymphocytes | 0.69 (0.55–0.88) | 0.003 |
| Pre-Operative Monocytes | 1.46 (0.91–2.36) | 0.11 |
| Pre-Operative Creatinine | 1.20 (1.09–1.31) | <0.001 |
| Pre-Operative Glucose | 1.00 (1.00–1.01) | <0.001 |
| Pre-Operative NLR | 1.09 (1.06–1.13) | <0.001 |
| | | |
| Internal mammary artery used | 0.35 (0.21–0.57) | <0.001 |
| Number of conduits used for bypass | 0.96 (0.82–1.13) | 0.64 |
| Renal failure on dialysis | 6.80 (3.91–11.80) | <0.001 |
| Cardiopulmonary bypass | 1.76 (1.11–2.79) | 0.01 |
| New onset atrial fibrillation | 2.03 (1.41–2.91) | <0.001 |
| Septicemia | 6.95 (3.54–13.65) | <0.001 |
CCS Canadian Cardiovascular Society Angina classification system, NLR neutrophil lymphocyte ratio, NYHA New York Heart Association Functional Classification.
NLR multivariate adjusted all-cause mortality Cox proportional hazard ratio in coronary bypass surgery patients
| Pre-Operative NLR (per unit) | 1.06 | 1.01–1.10 | 0.008 |
| Age (per year) | 1.07 | 1.05–1.09 | <0.001 |
| Male gender | 0.73 | 0.51–1.03 | 0.06 |
| Family history of coronary artery disease | 0.71 | 0.49–1.04 | 0.07 |
| Smoking | 1.37 | 0.96–1.95 | 0.08 |
| Preoperative renal failure on dialysis | 5.56 | 2.98–10.4 | <0.001 |
| Chronic pulmonary disease | 1.73 | 1.15–2.59 | 0.008 |
| In-hospital angiotensin convertase inhibitor | 1.41 | 1.00–1.99 | 0.05 |
| In-hospital statin | 0.37 | 0.20–0.67 | 0.001 |
| Aspirin on discharge | 0.29 | 0.15–0.56 | <0.001 |
| Postoperative renal failure on dialysis | 2.34 | 1.16–4.71 | 0.01 |
| Postoperative septicemia | 2.99 | 1.29–6.93 | 0.01 |
| Preoperative Glucose (pre mg/dl) | 1.01 | 1.00–1.01 | <0.001 |
NLR neutrophil lymphocyte ratio, HR hazard ratio, CI confidence interval.
Figure 3Kaplan-Meier Curve of mortality among patients undergoing coronary bypass surgery according to their neutrophil lymphocyte ratio (NLR) cutoffs: NLR <3 and NLR ≥3 (p = 0.002). The average follow-up was 49 ± 15.2 months (range 21–70 months). Total of 467 patients had 5-year follow up period.
Multivariate logistic regression models for all-cause mortality among patients with preoperative neutrophil lymphocyte ratio ≥3
| | |||
| MICS vs. Sternotomy CABG | 0.44 | 0.24–0.78 | 0.005 |
| Internal mammary artery used | 0.39 | 0.17–0.89 | 0.02 |
| Postoperative new onset atrial fibrillation | 1.72 | 1.01–2.93 | 0.04 |
| Beta blockers on discharge | 0.57 | 0.30–1.09 | 0.09 |
| In-hospital clopidogrel | 1.56 | 0.92–2.63 | 0.09 |
| | |||
| MICS vs. Sternotomy CABG | 0.50 | 0.28–0.90 | 0.02 |
| Age (per year) | 1.08 | 1.05–1.11 | <0.001 |
| Preoperative renal failure on dialysis | 10.05 | 3.46–29.19 | <0.001 |
| Internal mammary artery used | 0.48 | 0.20–1.12 | 0.08 |
Model A included history of prior coronary angioplasty, MICS vs. sternotomy CABG, postoperative new onset atrial fibrillation, use of internal mammary artery, use of cardiopulmonary bypass, clopidogrel on discharge and in-hospital, coumadin on discharge, beta blockers on discharge.
Model B included age, gender, family history of coronary artery disease, history of renal dialysis, statin on discharge, coumadin on discharge, use of internal mammary artery, MICS vs. sternotomy CABG and postoperative new onset atrial fibrillation.
MICS minimal invasive cardiac surgery (thoracotomy), CABG coronary artery bypass graft.